The inspection of the company's manufacturing unit at Chikalthana, Aurangabad by the UK Medicines and Healthcare products Regulatory Agency (MHRA) has been completed and there were no critical observations, Wockhardt Ltd said in a filing to the BSE.
Earlier this year, the US Food and Drug Administration (USFDA) had also not found any issues with respect to data security and control measures at the Mumbai-based drug maker's Chikalthana plant, but suggested continuous voluntary compliance for "desired quality culture".
Wockhardt shares today ended at Rs 1,541.15 apiece on the BSE, up 1.05 per cent from previous close.